Literature DB >> 19744837

Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy.

Paul R Ingram1, David C Lye, Dale A Fisher, Wei-Ping Goh, Vincent H Tam.   

Abstract

Intravenous (i.v.) vancomycin is increasingly used as outpatient parenteral antimicrobial therapy (OPAT). Despite the potential advantages of administration by continuous infusion (CI) compared with intermittent infusion (II), the relative nephrotoxicity of these two modes of delivery has not been well established. We compared the rate of nephrotoxicity of vancomycin given by CI and II. A retrospective cohort study of OPAT patients receiving i.v. vancomycin between January 2004 to June 2008 was performed. All patients had a normal baseline serum creatinine concentration. Propensity scoring analysis was used to adjust for risk factors of CI. The primary outcomes examined were the prevalence and rate of onset of nephrotoxicity. A total of 167 patients receiving vancomycin were identified, 112 by CI and 55 by II. The overall cumulative prevalence of nephrotoxicity was 15.6%. There were significant differences in baseline characteristics between the two groups. Matching based on propensity scores was undertaken, leaving 80 patients available for the analysis. Both in unadjusted and adjusted analyses, vancomycin CI was associated with a slower onset of nephrotoxicity but not a lower prevalence of nephrotoxicity. Both groups received a similar cumulative vancomycin dose. In adult OPAT patients with normal renal function, vancomycin CI was associated with a slower onset of nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19744837     DOI: 10.1016/j.ijantimicag.2009.07.011

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  18 in total

1.  Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries.

Authors:  A Canut; A Isla; C Betriu; A R Gascón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-28       Impact factor: 3.267

2.  Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model.

Authors:  Sheryl Zelenitsky; Noha Alkurdi; Zhanni Weber; Robert Ariano; George Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

3.  Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Maya Hites; Marjorie Beumier; Sabino Scolletta; Frédérique Jacobs
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

4.  Design and prospective validation of a dosing instrument for continuous infusion of vancomycin: a within-population approach.

Authors:  Erik M van Maarseveen; Annemien Bouma; Daniel J Touw; Cees Neef; Arthur R H van Zanten
Journal:  Eur J Clin Pharmacol       Date:  2014-08-30       Impact factor: 2.953

5.  Outpatient parenteral antimicrobial therapy.

Authors:  Kevin B Laupland; Louis Valiquette
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

6.  Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes.

Authors:  Vincent H Tam; Cary A Rogers; Kai-Tai Chang; Jaye S Weston; Juan-Pablo Caeiro; Kevin W Garey
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

7.  Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design.

Authors:  Kamilia Abdelraouf; Kirk H Braggs; Taijun Yin; Luan D Truong; Ming Hu; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

8.  Kidney injury associated with telavancin dosing regimen in an animal model.

Authors:  Vincent H Tam; Kimberly R Ledesma; Dana R Bowers; Jian Zhou; Luan D Truong
Journal:  Antimicrob Agents Chemother       Date:  2015-02-23       Impact factor: 5.191

Review 9.  Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice.

Authors:  Fawzy Elbarbry
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-06       Impact factor: 2.441

Review 10.  Vancomycin-Induced Kidney Injury: Animal Models of Toxicodynamics, Mechanisms of Injury, Human Translation, and Potential Strategies for Prevention.

Authors:  Gwendolyn M Pais; Jiajun Liu; Sanja Zepcan; Sean N Avedissian; Nathaniel J Rhodes; Kevin J Downes; Ganesh S Moorthy; Marc H Scheetz
Journal:  Pharmacotherapy       Date:  2020-05-04       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.